{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:54:50Z","timestamp":1761519290894,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.clbc.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T12:24:34Z","timestamp":1552307074000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"Maki","family":"Namura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsutoshi","family":"Enokido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koyu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideko","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2019.03.001_bib1","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/cncr.23083","article-title":"Preoperative chemotherapy treatment of breast cancer\u2212a review","volume":"110","author":"Buzdar","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2019.03.001_bib2","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update","volume":"24","author":"Kaufmann","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib3","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ejso.2015.07.020","article-title":"The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review and meta-analysis","volume":"41","author":"van Nijnatten","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib4","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer:findings from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib5","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1245\/s10434-013-2992-8","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node positive breast cancer at diagnosis","volume":"20","author":"Park","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib6","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1245\/s10434-012-2484-2","article-title":"The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer","volume":"19","author":"Alvarado","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.clbc.2013.08.014","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer","volume":"13","author":"Yagata","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2019.03.001_bib8","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.clbc.2016.06.020","article-title":"Feasibility and prognostic effect of sentinel lymph node biopsy after neoadjuvant chemotherapy in cytology-proven, node-positive breast cancer","volume":"17","author":"Parl","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2019.03.001_bib9","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","article-title":"How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? results of a prospective study","volume":"23","author":"Mamtani","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib10","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2019.03.001_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-007-9744-z","article-title":"Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival","volume":"110","author":"Toi","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2019.03.001_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.amjsurg.2011.09.026","article-title":"Axillary ultrasound examination is useful for selecting patients optimally suited for sentinel lymph node biopsy after primary systemic chemotherapy","volume":"204","author":"Shigekawa","year":"2012","journal-title":"Am J Surg"},{"key":"10.1016\/j.clbc.2019.03.001_bib13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.breast.2016.11.012","article-title":"Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - results from the multi-center SENTINA trial","volume":"31","author":"Schwentner","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2019.03.001_bib15","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2019.03.001_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicenter cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib17","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1200\/JCO.2013.54.1177","article-title":"Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"32","author":"Lyman","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib18","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1200\/JCO.2005.03.228","article-title":"Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial","volume":"23","author":"Purushotham","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2\u2013positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomized trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib20","first-page":"520","article-title":"Long-term outcomes of neoadjuvant treatment of HER2\u2013positive breast cancer","volume":"14","author":"Zhang","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib21","doi-asserted-by":"crossref","first-page":"e1720","DOI":"10.1097\/MD.0000000000001720","article-title":"Prognostic nomogram for prediction of axillary pathologic complete response after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer","volume":"94","author":"Kim","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clbc.2019.03.001_bib22","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/cncr.25152","article-title":"Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer","volume":"116","author":"Dominici","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2019.03.001_bib23","doi-asserted-by":"crossref","first-page":"56626","DOI":"10.18632\/oncotarget.17993","article-title":"Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab","volume":"8","author":"Ding","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2019.03.001_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib25","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jcp.2007.054866","article-title":"HER2 testing in the UK: further update to recommendations","volume":"61","author":"Walker","year":"2008","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clbc.2019.03.001_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.clbc.2016.02.009","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in patients with an initial diagnosis of cytology-proven lymph node-positive breast cancer","volume":"16","author":"Enokido","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2019.03.001_bib27","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2014.57.8401","article-title":"Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American college of surgeons oncology group Z1071 Trial (Alliance)","volume":"33","author":"Boughey","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib28","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib29","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/bjs.7073","article-title":"Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer","volume":"97","author":"Straver","year":"2010","journal-title":"Br J Surg"},{"key":"10.1016\/j.clbc.2019.03.001_bib30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","article-title":"Making axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure","volume":"261","author":"Donker","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.clbc.2019.03.001_bib31","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2019.03.001_bib32","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.clbc.2017.09.013","article-title":"The prognostic effect of changes in tumor stage and nodal status after neoadjuvant chemotherapy in each primary breast cancer subtype","volume":"18","author":"Hayashi","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2019.03.001_bib33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2019.03.001_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918308589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918308589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:18:08Z","timestamp":1761513488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820918308589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1526820918308589"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2019.03.001","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}